Charlevoix-Saguenay Spastic Ataxia

Charlevoix-Saguenay spastic ataxia is a rare genetic brain and nerve disease that mainly affects movement. Doctors also call it ARSACS. In this disease, the brain area that controls balance (the cerebellum), the long nerve pathways to the legs (pyramidal tracts), and the nerves in the arms and legs (peripheral nerves) slowly get damaged. This damage causes problems with walking, balance, stiff legs, and weakness or numbness in hands and feet. Symptoms usually start in early childhood when a child begins to walk and then slowly get worse over many years. NCBI+2MedlinePlus+2

Charlevoix-Saguenay spastic ataxia, also called autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), is a rare inherited brain and nerve disease. It is caused by changes (mutations) in the SACS gene. This gene normally helps keep certain brain cells, especially Purkinje cells in the cerebellum, healthy. When the gene does not work, these cells slowly become damaged and die. People with ARSACS usually have stiff muscles (spasticity), poor balance and coordination (ataxia), and weakness and numbness in arms and legs (peripheral neuropathy).MedlinePlus+1

Symptoms usually start in early childhood when a child learns to walk. Children may fall often, walk with a wide-based, unsteady gait, and have trouble with fine hand movements. Over many years the condition slowly worsens. Many people need a wheelchair in adult life, often by age 30–40, but life span can still be long. At present there is no cure and no disease-specific approved drug, so treatment focuses on easing symptoms, keeping independence, and preventing complications.National Ataxia Foundation+2NxGen MDx+2

Other names

Doctors and books may use several other names for the same disease. All of the names below describe the same condition:

• Autosomal recessive spastic ataxia of Charlevoix-Saguenay

• ARSACS

• Spastic ataxia, Charlevoix-Saguenay type

• Autosomal recessive spastic ataxia type 6

These names show that the disease is inherited (autosomal recessive), causes stiffness (spastic) and poor balance (ataxia), and was first found in people from the Charlevoix and Saguenay-Lac-Saint-Jean regions of Québec in Canada. Wikipedia+2MedlinePlus+2

Types

Doctors now know that ARSACS does not look exactly the same in every person. There are different clinical “types” or patterns, mainly based on age when symptoms start and how fast they progress: NCBI+2Orpha.net+2

• Classic early-onset type
  This is the original and most common pattern. Symptoms start in late infancy or early childhood, often around 12–24 months, when a child learns to walk. The child has unsteady walking, frequent falls, and later develops stiff legs and nerve problems in the hands and feet.

• Childhood-onset outside Québec
  In people from countries outside Québec, symptoms often still start in childhood, but the exact age can be later and the course may vary. Some children walk a bit later than usual because of poor balance and coordination.

• Adolescent- or adult-onset (atypical type)
  Some people develop symptoms in the teenage years or even in adulthood. These cases may have milder ataxia at first, sometimes more obvious nerve damage or spasticity, and can be confused with other ataxia or spastic paraplegia disorders before genetic testing.

• Complex or “expanded spectrum” type
  Research has shown that some people with ARSACS can also have vision problems, swallowing difficulties, speech problems, mood or thinking changes, or seizures. In these people, the disease picture is more complex, but the same gene is involved. NCBI+2Journal MedDBU+2

Causes

The main cause of Charlevoix-Saguenay spastic ataxia is a mutation (change) in a gene called SACS on chromosome 13. This gene gives the instructions to make a large protein called sacsin. When the gene is damaged in both copies, the protein does not work properly, and certain brain and nerve cells slowly become sick and die. NCBI+2MedlinePlus+2

Below are 20 closely related “causes and mechanisms.” It is important to remember that they all come from the same root problem: SACS gene mutations inherited in an autosomal recessive way.

1. SACS gene mutation
   The direct cause is a harmful change in both copies of the SACS gene. Each parent usually carries one faulty copy but is healthy. When a child inherits the faulty copy from both parents, the child develops ARSACS. NCBI+1

2. Autosomal recessive inheritance
   The disease follows an autosomal recessive pattern. This means the gene is on a non-sex chromosome and both gene copies must have mutations. Brothers or sisters of an affected person have a 25% chance of also having the disease if both parents are carriers. MedlinePlus+1

3. Founder effect in Charlevoix-Saguenay region
   In the Charlevoix and Saguenay-Lac-Saint-Jean regions of Québec, several old shared mutations are common in the population. Because of this founder effect, ARSACS is much more frequent there than in most other places in the world. Wikipedia+1

4. Consanguinity (parents related by blood)
   In some families from outside Québec, parents are cousins or more closely related. When parents share ancestors, they are more likely to carry the same rare SACS mutation, which increases the chance that a child will inherit two faulty copies. NCBI+1

5. Loss of sacsin protein function
   The SACS gene makes sacsin, a large protein that helps proteins fold correctly and supports cell structures called intermediate filaments and mitochondria. Mutations cause loss or severe reduction of sacsin function, which stresses and injures nerve cells. NCBI+1

6. Mitochondrial dysfunction in neurons
   Studies show that sacsin problems disturb mitochondria, the “power plants” inside cells. Damaged mitochondria produce less energy and more harmful reactive molecules. This is especially bad for long nerve cells that need a lot of energy, leading to progressive damage. NCBI+1

7. Purkinje cell loss in the cerebellum
   Purkinje cells are key nerve cells in the cerebellum that control coordination. In ARSACS, these cells slowly degenerate and die, causing ataxia, clumsy movements, and poor balance. NCBI+1

8. Degeneration of long motor pathways (pyramidal tracts)
   The long nerve fibers that run from the brain to the spinal cord and control leg muscles become damaged. This damage causes stiffness, high muscle tone, and brisk reflexes in the legs, which doctors call spasticity and pyramidal signs. NCBI+2Journal MedDBU+2

9. Peripheral nerve damage (axonal neuropathy)
   The long nerves that bring signals to and from the arms and legs slowly lose their fibers (axons). This peripheral neuropathy causes numbness, tingling, weakness, and muscle wasting in the hands and feet over time. NCBI+2Journal MedDBU+2

10. Abnormal intermediate filament network in nerve cells
    Sacsin helps maintain the network of intermediate filaments inside nerve cells. Without sacsin, these filaments become disorganized. This structural problem likely contributes to the slow death of these cells. NCBI

11. White-matter changes in the brain
    MRI studies show abnormal white-matter pathways (the “wiring” between brain regions) in ARSACS. These changes reflect long-standing damage to nerve fibers and help explain problems with movement, speech, and sometimes thinking. NCBI+1

12. Cerebellar atrophy
    Over time, the cerebellum becomes smaller and shows atrophy on MRI. The shrinking of this balance and coordination center is another important part of the disease mechanism. NCBI+1

13. Pontine stripes on MRI
    A typical feature in ARSACS is special dark stripes in the pons (part of the brainstem) on T2 MRI images. These stripes show abnormal bundles of nerve fibers and are a sign of long-term structural change in the brain. NCBI+2Journal MedDBU+2

14. Retinal nerve fiber thickening
    Some patients show thick nerve fiber layers in the retina on eye imaging. This suggests that sacsin problems affect not only brain and spinal nerves but also visual nerve fibers. NCBI

15. Muscle wasting from long-term nerve damage
    Because the nerves to the limbs are damaged, muscles do not receive normal signals. Over time, these muscles become thin and weak (amyotrophy), especially in the lower legs and hands. Journal MedDBU+1

16. Pes cavus and skeletal deformities
    Long-term imbalance between weak and strong muscles around the feet and spine leads to high-arched feet (pes cavus), hammertoes, and sometimes scoliosis (curved spine). These are consequences of the nerve and muscle disease. Journal MedDBU+1

17. Damage to speech and swallowing circuits
    ARSACS can involve brain regions and nerve pathways that control the tongue, throat, and facial muscles. This leads to slurred speech (dysarthria) and difficulty swallowing (dysphagia) in many patients. NCBI+2Journal MedDBU+2

18. Possible involvement of cognitive and emotional circuits
    Some reports describe problems with attention, planning, or mood in people with ARSACS. This suggests that areas of the cerebellum and brain networks related to thinking and emotions may also be affected. NCBI+1

19. Worldwide spread of different SACS mutations
    Many different SACS mutations have been found in families in Europe, Asia, and other parts of the world. These different mutations can all lead to similar damage patterns in the nervous system. NCBI+2Journal MedDBU+2

20. No known environmental cause
    There is no proof that food, infections, injuries, or toxins cause ARSACS by themselves. The disease is genetic. However, general health, infections, or injuries may temporarily worsen symptoms in someone who already has the condition. NCBI+1

Symptoms

1. Unsteady walking and frequent falls
   One of the first signs in young children is an unsteady, wide-based walk. They fall easily and may look clumsy compared with other children the same age. This comes from damage to the cerebellum and long nerve tracts that control balance and coordination. Wikipedia+2NCBI+2

2. Spasticity (stiff, tight leg muscles)
   The leg muscles gradually become stiff and tight. The knees and ankles are hard to bend smoothly, and the legs may feel like they resist movement. This spasticity is due to damage in the brain and spinal cord pathways that normally control muscle tone. NCBI+2Journal MedDBU+2

3. Cerebellar ataxia (poor coordination)
   People with ARSACS have ataxia, which means poor coordination of arms, legs, and body. They can have trouble with tasks that require precise control, such as reaching, writing, or buttoning clothes. Movements may seem shaky or inaccurate. Wikipedia+2NCBI+2

4. Peripheral neuropathy (numbness and tingling)
   Over time, many people lose normal feeling in their feet and hands. They may feel numbness, tingling, burning, or reduced ability to feel temperature, pain, or vibration. This comes from damage to the long peripheral nerves. NCBI+2Journal MedDBU+2

5. Weakness and muscle wasting in legs and hands
   The muscles, especially in the lower legs and small muscles of the hands, can become weak and thin. People may have trouble climbing stairs, standing from a chair, or performing fine hand tasks. Journal MedDBU+1

6. Pes cavus (high-arched feet) and toe deformities
   Many patients develop very high arches in their feet and hammertoes. These changes are typical in people with long-standing nerve damage to the legs and feet and can cause pain and problems with footwear and walking. Journal MedDBU+1

7. Horizontal gaze nystagmus (jerky eye movements)
   Some people have rapid, involuntary, side-to-side eye movements called nystagmus. They may notice shaking vision or difficulty focusing. This sign shows cerebellar and brainstem involvement. Wikipedia+1

8. Dysarthria (slurred, slow speech)
   Speech can become slow, slurred, or scanning (words broken into separate parts). This happens because the muscles used for speech are affected by ataxia and spasticity, and the brain circuits that time and coordinate speech are damaged. NCBI+1

9. Dysphagia (difficulty swallowing)
   Some people with ARSACS have trouble swallowing liquids or solids. They may cough or choke when eating or drinking. This is due to weakness and poor coordination in the muscles of the mouth and throat and can increase the risk of chest infections. NCBI+1

10. Bladder problems
    People may have urinary urgency (sudden strong need to urinate), frequency, or difficulty holding urine. This is probably related to spasticity and nerve pathway changes that control the bladder. Journal MedDBU+1

11. Scoliosis (curved spine)
    Over time, abnormal muscle pull and weak trunk muscles can lead to sideways curvature of the spine. Scoliosis may cause back pain and make sitting or breathing more difficult in advanced cases. Journal MedDBU+1

12. Vision changes
    Some patients have thickened retinal nerve fiber layers or other eye changes on special scans. They may have blurry vision or other sight problems, although not everyone notices symptoms. NCBI+1

13. Fatigue and reduced endurance
    Because movements are inefficient and require more effort, people often feel tired after walking short distances or doing daily tasks. Nerve and muscle problems plus spasticity make activity more exhausting. NCBI+2Journal MedDBU+2

14. Seizures (in some patients)
    A minority of people with ARSACS have epileptic seizures. This shows that in some cases, the disease process also affects brain areas that can trigger abnormal electrical activity. Journal MedDBU+1

15. Cognitive or emotional changes (in some patients)
    Some case reports describe problems with thinking skills, planning, or mood, called cerebellar cognitive affective syndrome. Not everyone has these problems, but when present, they are part of the wider brain involvement in ARSACS. NCBI+1

Diagnostic tests

Doctors use many tests together to diagnose Charlevoix-Saguenay spastic ataxia. They combine the story, the physical exam, special bedside (manual) tests, lab tests including genetic testing, electrodiagnostic tests, and brain imaging.

Physical examination tests

1. Full neurological examination
   The doctor looks at muscle strength, reflexes, muscle tone, balance, and coordination. In ARSACS, they often find stiff legs (spasticity), brisk reflexes, weakness and wasting in the feet and hands, and poor coordination of arms and legs. These findings guide the doctor to think about a combined ataxia and spastic paraplegia with neuropathy. NCBI+2Journal MedDBU+2

2. Gait and posture assessment
   The doctor watches how the person stands, walks, turns, and sits. People with ARSACS often have a wide-based, unsteady gait, may scuff their feet, and may use support such as a cane or walker. Over years, many people need a wheelchair. Wikipedia+2NCBI+2

3. Muscle tone and reflex testing
   The doctor moves the legs and arms to feel how stiff they are and taps tendons to check reflexes. In ARSACS, there is usually increased tone and brisk reflexes in the legs, sometimes with ankle clonus and up-going plantar responses (Babinski sign), showing damage to long motor pathways. NCBI+2Journal MedDBU+2

4. Sensory examination
   The doctor tests touch, pain, vibration, and position sense using simple tools like cotton, a pin, or a tuning fork. Reduced sensation in the feet and sometimes hands suggests peripheral neuropathy, which is a key feature of ARSACS. NCBI+2Journal MedDBU+2

5. Eye movement and speech examination
   The doctor looks at how the eyes move in all directions and listens to speech. Nystagmus (jerky eye movements) and scanning or slurred speech support cerebellar involvement, which fits with ARSACS when combined with other signs. Wikipedia+2NCBI+2

Manual (bedside functional) tests

6. Finger-to-nose test
   The person is asked to touch their nose and then the doctor’s finger in front of them, moving back and forth. In ARSACS, the hand may miss the target or show shaky movements near the target (intention tremor), showing limb ataxia. NCBI+1

7. Heel-to-shin test
   Lying down, the person is asked to slide the heel of one foot along the shin of the opposite leg. In ARSACS, this movement can be wobbly, uneven, or hard to control, which is another sign of cerebellar ataxia. NCBI+1

8. Rapid alternating movement tests
   The doctor asks the person to quickly flip their hand back and forth on their lap or tap finger and thumb together rapidly. In ARSACS, these movements tend to be slow, irregular, or poorly timed, reflecting impaired motor coordination. NCBI+1

9. Romberg and balance tests
   The person stands with feet together, first with eyes open and then closed. Loss of balance, especially with eyes closed, shows problems with coordination and sensation. Combined with other signs, this supports the diagnosis of a mixed cerebellar and sensory ataxia like ARSACS. NCBI+1

10. Timed walking and functional mobility tests
    Simple timed tests, such as how long it takes to stand up from a chair, walk a short distance, turn, and sit down, help measure how severe the gait and balance problems are. These tests are useful to follow disease progression and response to rehabilitation. National Ataxia Foundation+1

Laboratory and pathological tests

11. Targeted SACS gene testing
    This is the most important lab test. If ARSACS is suspected, the blood is tested for known SACS mutations, especially founder mutations in people from Québec or known frequent variants in other populations. Finding two disease-causing mutations confirms the diagnosis. NCBI+2MedlinePlus+2

12. Ataxia gene panel or whole-exome sequencing
    In many centers, doctors order a panel that tests many ataxia-related genes at once, or even whole-exome sequencing. This approach can find SACS mutations in people where ARSACS was not first suspected, and helps distinguish it from other inherited ataxias and spastic paraplegias. NCBI+2ScienceDirect+2

13. Basic blood tests to exclude other causes
    Tests for vitamin B12, vitamin E, thyroid hormones, liver and kidney function, and autoimmune markers are often done. These tests do not diagnose ARSACS but help rule out other treatable causes of ataxia and neuropathy so that inherited causes like ARSACS are considered more strongly. NCBI+1

14. Nerve or muscle biopsy (rare and usually historical)
    In the past, doctors sometimes took a small sample of nerve or muscle tissue to study under a microscope. They could see signs of axonal neuropathy or other changes. Today, biopsy is rarely needed because genetic testing and modern imaging are more specific and less invasive. NCBI+1

15. Cerebrospinal fluid (CSF) analysis
    A lumbar puncture to collect spinal fluid is not usually required for ARSACS, but it may be done if another disease such as inflammation or infection is suspected. A normal CSF result supports the idea of a genetic, non-inflammatory ataxia like ARSACS. NCBI+1

Electrodiagnostic tests

16. Nerve conduction studies (NCS)
    Small electrical pulses are applied to nerves in the arms and legs, and responses are recorded. In ARSACS, these tests typically show reduced amplitude of sensory and sometimes motor responses, meaning loss of nerve fibers (axonal neuropathy). This pattern supports the diagnosis. NCBI+2Journal MedDBU+2

17. Electromyography (EMG)
    A fine needle electrode is inserted into muscles to record electrical activity. EMG in ARSACS often shows signs of chronic denervation and re-innervation, which confirms that the muscle weakness and wasting come from long-standing nerve damage rather than a primary muscle disease. NCBI+1

18. Evoked potential studies
    In some patients, doctors may record visual, auditory, or somatosensory evoked potentials. These tests measure how quickly signals travel along certain nerve pathways. Abnormal results can show additional involvement of sensory pathways in the brain and spinal cord. NCBI+1

Imaging tests

19. Brain MRI (key imaging test)
    Brain MRI is very important for diagnosing ARSACS. Typical findings include thinning and atrophy of the cerebellum, especially the superior part, and characteristic dark stripes in the pons on T2 images. There may also be abnormal white-matter signals in the brain. When these MRI signs are seen together with the clinical triad and SACS mutations, the diagnosis is very strong. NCBI+2Journal MedDBU+2

20. Spinal cord and nerve root MRI
    MRI of the spinal cord can show thinning of certain tracts and sometimes atrophy. Although changes are less specific than in the brain, spinal imaging helps rule out other structural problems (such as tumors or severe disc disease) that could also cause spasticity and weakness. NCBI+2Journal MedDBU+2

Non Pharmacological Treatments (Therapies and Other Approaches)

1. Physiotherapy for gait and balance
Physiotherapy is one of the most important non-drug treatments in Charlevoix-Saguenay spastic ataxia. The therapist teaches exercises to improve balance, walking pattern, and coordination, and to keep muscles flexible. Studies in people with ARSACS show that structured rehabilitation programs with strengthening and balance exercises can improve mobility, endurance, and daily activities.PMC+1 The main purpose is to delay loss of walking and reduce falls. The mechanism is simple: repeated practice helps the nervous system use remaining pathways more efficiently and keeps muscles and joints from becoming stiff or weak.

2. Stretching and range-of-motion exercises
Daily stretching of legs, hips, and ankles helps reduce tight muscles and prevent contractures (permanent joint stiffness). In spasticity, muscle tone is increased and muscles resist quick movement.Physiopedia Slow, regular stretching tells the spinal cord reflex circuits to relax and allows muscles and tendons to lengthen. GeneReviews recommends early physical therapy and stretching to limit tendon shortening and joint contractures in ARSACS.NCBI+1

3. Strengthening exercises
Targeted strengthening of core muscles, hip muscles, and upper limbs can help support posture and function. In ARSACS, weakness from neuropathy and disuse can add to ataxia and falls. A strengthening program with low to moderate resistance and many repetitions helps motor units fire more effectively without causing too much fatigue. Case reports show that strengthening plus balance training improves walking tests and coordination in ARSACS.DergiPark+1

4. Balance and coordination training (including exergames)
Balance training may include standing on different surfaces, stepping in various directions, and using body-weight shifts. Some programs use “exergames” or virtual reality games designed for ataxia to make training more engaging. GeneReviews mentions physiotherapy and exergames tailored to ataxia for ARSACS.NCBI+1 These games provide visual feedback and repeated practice, helping the brain adjust posture and timing. The purpose is better stability and fewer falls.

5. Occupational therapy (OT)
Occupational therapists focus on daily activities such as dressing, using a computer, cooking, and personal care. They may suggest adaptive tools (built-up handles, shower chairs, grab bars) and energy-saving techniques. In ARSACS, OT helps people keep independence at home and work for as long as possible. By modifying tasks and environments instead of the disease itself, OT reduces fatigue and the risk of accidents.genopedia.com+1

6. Speech and language therapy
Many people develop slurred speech (ataxic dysarthria) and sometimes swallowing problems. Speech-language therapy can improve clarity of speech and safety of swallowing. An intensive home-based program for ARSACS has shown improvement in speech timing and intelligibility.ataxia.org.uk+1 Exercises focus on breath support, loudness, articulation, and safe swallowing strategies. The purpose is to keep communication as clear as possible and reduce the risk of choking or aspiration.

7. Home-based exercise programs
The ARSACS Foundation has developed a structured home exercise program including sitting balance, standing balance, and sit-to-stand training.ARSACS+1 After an assessment by a physiotherapist, patients can follow tailored exercises at home. This program uses short daily sessions to maintain gains between clinic visits. The mechanism is “distributed practice”: many small, regular doses of training help the nervous system keep skills and prevent decline.

8. Orthotic devices (braces and splints)
Orthotic devices such as ankle–foot orthoses (AFOs), wrist splints, or hand braces can improve alignment, reduce toe-drag, and prevent contractures. GeneReviews suggests using orthoses early in ARSACS to protect tendons and joints.NCBI+1 By holding joints in a functional position, orthoses reduce the energy cost of walking and make movements safer and more efficient.

9. Walking aids (canes, walkers, rollators)
Many people with Charlevoix-Saguenay spastic ataxia benefit from walking aids as the disease progresses. A cane, walking frame, or rollator gives extra support points and widens the base of support. This reduces fear of falling and allows longer distances with less fatigue. The mechanism is mechanical: the device carries part of the body weight and stabilizes the center of gravity, which is especially useful in ataxia and spasticity.PMC+1

10. Wheelchair and seating management
When walking becomes very difficult, a manual or powered wheelchair can greatly increase independence. Good seating with proper cushions, trunk supports, and headrests is essential to prevent pressure sores and scoliosis. Rehabilitation specialists and occupational therapists adjust chair settings to match body shape and movement pattern. This improves comfort, protects the skin, and allows participation in school, work, and social activities.

11. Posture and spinal care programs
Long-term spasticity and weakness can cause abnormal posture and spinal curvature. Regular monitoring and exercises for trunk control, along with proper seating and sometimes corsets, may slow scoliosis.ResearchGate+1 The purpose is to keep the chest open for breathing, reduce back pain, and make transfers and wheelchair sitting more comfortable.

12. Fall-prevention and home safety adaptation
Occupational therapists can assess the home environment and suggest changes such as removing loose rugs, installing grab bars, improving lighting, and using non-slip shoes. These simple measures reduce the chance of falls, which are a major risk because of ataxia and spasticity.PMC+1 The mechanism is environmental control: instead of changing the person, we change the surroundings to be safer.

13. Respiratory physiotherapy and fitness training
Later in the disease, some people develop reduced physical capacity and weaker breathing muscles. Gentle aerobic exercise (like arm cycling or seated stepping) and breathing exercises can help maintain lung function and reduce chest infections. In neurological diseases, regular aerobic activity improves endurance and mood, and may slow deconditioning.PMC+1

14. Vision and oculomotor training
Some people with ARSACS have eye movement problems and retinal nerve fiber changes.NCBI+1 Neuro-ophthalmology assessment and simple oculomotor exercises (like tracking and saccade training) may help reduce visual discomfort and support reading and mobility. The goal is to optimize remaining visual function and reduce dizziness or imbalance triggered by visual problems.

15. Assistive communication technology
If speech becomes hard to understand, communication devices such as text-to-speech apps, symbol boards, or eye-gaze systems can be used. These tools allow a person to express needs and feelings even when speech is limited. Maintaining communication reduces social isolation and depression and keeps the person actively involved in decisions about their own care.

16. Psychological counselling and mental health support
Living with a progressive rare disease is stressful for the person and family. Psychological counselling, cognitive-behavioural therapy, and support groups can reduce anxiety and depression.PMC+1 The mechanism is emotional coping: learning skills to handle loss of independence and uncertainty improves quality of life.

17. Social work and community support services
Social workers help families access disability benefits, transport support, home care, and school or workplace accommodations. In rare diseases with progressive disability, access to appropriate services is a key part of treatment.ARSACS+1 This support reduces caregiver burden and helps plan for future needs.

18. Genetic counselling
Because ARSACS is autosomal recessive, each sibling of an affected person has a 25% chance of also having the condition.MedlinePlus+1 Genetic counselling explains inheritance, carrier testing, and reproductive options. The purpose is to give families clear information so they can make informed choices for the future.

19. Education and vocational rehabilitation
School-age children may need special education supports, extra time, and physical accommodations. Later, vocational rehabilitation can help match a person’s abilities with suitable jobs and provide workplace modifications. The goal is to keep people with Charlevoix-Saguenay spastic ataxia engaged in education and work as long as possible.

20. Patient organizations and peer support
Organizations such as the Ataxia Charlevoix-Saguenay Foundation and ataxia associations provide information, advocacy, and peer connections.ARSACS+1 Meeting others with the same condition can reduce feelings of isolation, share practical tips, and give hope by highlighting ongoing research and clinical trials.

---

Drug Treatments for Symptoms in Charlevoix-Saguenay Spastic Ataxia

Important note: No medicine currently cures ARSACS, and many drugs are used off-label to treat symptoms like spasticity, pain, or bladder problems. Dosages below are typical adult ranges from FDA-approved prescribing information for related conditions such as multiple sclerosis or neuropathic pain, not specific dosing advice for ARSACS. Always follow a specialist’s prescription and never change the dose without medical guidance.NxGen MDx+1

1. Oral baclofen
Baclofen is a GABA-B receptor agonist approved for spasticity related to spinal cord disease and multiple sclerosis. FDA labels (for products such as LYVISPAH, OZOBAX, and FLEQSUVY) suggest starting at 5 mg three times daily and slowly increasing to a usual maximum of 80 mg/day, divided into several doses.FDA Access Data+2FDA Access Data+2 In ARSACS, baclofen can reduce leg stiffness, improve ease of walking, and make physiotherapy more effective. Common side effects include sleepiness, dizziness, weakness, and nausea; sudden stopping can cause withdrawal symptoms.

2. Intrathecal baclofen (baclofen pump)
For severe spasticity not controlled by tablets, baclofen can be delivered directly into the spinal fluid through an implanted pump (Lioresal Intrathecal, Gablofen).FDA Access Data+1 The dose is much lower than oral doses but acts strongly on spinal receptors to relax muscles. The purpose is to reduce painful spasms and help care such as transfers and hygiene. Side effects include weakness, infection or problems with the pump, and serious withdrawal if the drug is suddenly interrupted, so careful monitoring is essential.

3. Tizanidine (Zanaflex, Ontralfy)
Tizanidine is an alpha-2 adrenergic agonist approved by the FDA for spasticity. It is usually started at 2–4 mg up to three times a day and slowly increased, with a maximum daily dose around 24–36 mg, depending on the product label.FDA Access Data+2FDA Access Data+2 In Charlevoix-Saguenay spastic ataxia, tizanidine can help relax muscles, especially during activities when relief is most needed. Side effects include drowsiness, dry mouth, low blood pressure, and possible liver enzyme increases, so liver tests and blood pressure checks are important.

4. Dantrolene
Dantrolene is a skeletal muscle relaxant that acts directly on muscle cells to reduce calcium release from the sarcoplasmic reticulum, lowering contraction strength. It is FDA-approved for chronic spasticity and malignant hyperthermia.FDA Access Data+2FDA Access Data+2 Typical adult oral dosing for spasticity starts at 25 mg daily and is slowly increased to 100 mg three or four times a day, if tolerated.NCBI+1 In ARSACS, it may reduce severe stiffness but carries a risk of liver toxicity, so it is usually reserved for selected cases with liver function monitoring.

5. Botulinum toxin type A injections
Botulinum toxin injections (for example, onabotulinumtoxinA and related products) are FDA-approved for focal spasticity in several conditions. They block acetylcholine release at the neuromuscular junction in injected muscles, producing temporary relaxation.ScienceDirect+1 In ARSACS, botulinum toxin can be used for very tight calf muscles, hamstrings, or hip adductors, combined with physiotherapy and casting. Injections are usually repeated every three to four months. Side effects include local weakness and, rarely, spread of toxin effect.

6. Gabapentin (Neurontin and generics)
Gabapentin is an anticonvulsant approved for partial seizures and post-herpetic neuralgia.FDA Access Data+2FDA Access Data+2 It binds to calcium channel subunits and reduces abnormal nerve firing. Typical adult dosing for neuropathic pain is 300 mg once on day one, 300 mg twice on day two, then 300 mg three times daily, adjusting up to 1800–3600 mg/day in divided doses if needed. In Charlevoix-Saguenay spastic ataxia, gabapentin can help burning or tingling neuropathic pain and may slightly ease spasticity, but side effects like drowsiness, dizziness, and weight gain must be watched.

7. Pregabalin
Pregabalin is a related drug used for neuropathic pain and fibromyalgia. It works similarly to gabapentin by modulating calcium channels and reducing excitatory neurotransmitter release. Typical adult doses for neuropathic pain start at 75 mg twice daily and can increase to 150 mg twice daily or 100 mg three times daily, depending on kidney function.NCBI+1 In ARSACS, pregabalin may be preferred if gabapentin is not tolerated. Side effects include dizziness, sleepiness, swelling, and weight gain.

8. Duloxetine
Duloxetine is a serotonin–noradrenaline reuptake inhibitor (SNRI) approved for major depression, anxiety, and diabetic neuropathic pain. It increases serotonin and noradrenaline in the spinal cord, which can reduce pain signaling. Typical dosing is 30–60 mg once daily. In Charlevoix-Saguenay spastic ataxia, duloxetine can help neuropathic pain and depression at the same time. Side effects may include nausea, dry mouth, sweating, and changes in blood pressure.

9. Amitriptyline
Amitriptyline is a tricyclic antidepressant often used at low doses (10–75 mg at night) for neuropathic pain and sleep problems. It blocks reuptake of serotonin and noradrenaline and has anticholinergic effects. In ARSACS, it may ease burning pain and improve sleep, but can cause dry mouth, constipation, blurred vision, and daytime drowsiness, so it must be used carefully, especially in older adults and those with heart disease.

10. NSAIDs (e.g., ibuprofen, naproxen)
Non-steroidal anti-inflammatory drugs are not specific to ARSACS, but they can help musculoskeletal pain from overuse, falls, or joint strain. They work by blocking cyclo-oxygenase enzymes and lowering prostaglandin production, which reduces inflammation and pain. Typical short-term adult doses are ibuprofen 200–400 mg every 6–8 hours or naproxen 250–500 mg twice daily, within label limits. Side effects include stomach irritation, kidney strain, and increased bleeding risk.

11. Tolterodine or oxybutynin for bladder urgency
GeneReviews notes that urinary urgency in ARSACS can be treated with oral medications such as tolterodine, amitriptyline, or oxybutynin.NCBI+1 These drugs reduce overactive bladder contractions by blocking muscarinic receptors. Doses depend on the specific product (for example, tolterodine ER 2–4 mg once daily). Side effects include dry mouth, constipation, and blurred vision, so careful balancing of benefit and side effects is needed.

12. Antidepressants (e.g., sertraline, fluoxetine)
Living with a progressive disorder often leads to depression or anxiety. SSRIs such as sertraline or fluoxetine are FDA-approved for these conditions. They work by increasing serotonin levels in the brain. Typical starting doses are sertraline 25–50 mg daily and fluoxetine 10–20 mg daily. In ARSACS, treating mood problems is important because it improves motivation for therapy and overall quality of life. Side effects can include nausea, sleep changes, and, rarely, increased anxiety at the start.

13. Melatonin for sleep regulation
Melatonin is a hormone that helps regulate the sleep–wake cycle. Over-the-counter melatonin (often 1–5 mg at bedtime) is sometimes used to improve sleep in neurological disease. It acts on melatonin receptors in the brain to promote drowsiness. Better sleep can indirectly improve daytime energy, mood, and participation in therapy. Side effects are generally mild but can include vivid dreams and daytime drowsiness.

14. Vitamin D as a prescribed supplement
Although often thought of as a supplement, vitamin D is also a regulated drug in higher doses. It supports bone health and immune function. People with limited mobility may have low vitamin D due to less sun exposure. Typical regimens include daily doses (e.g., 800–2000 IU) or weekly higher doses, guided by blood levels. Adequate vitamin D may reduce fracture risk in people with frequent falls and improve muscle function.ataxia.org.uk+1

15. Other symptom-specific drugs
Depending on individual problems, doctors may use additional medicines such as proton pump inhibitors for reflux, laxatives for constipation, or pain medicines like acetaminophen. These are chosen case by case to treat specific symptoms rather than ARSACS itself. Because many drugs interact and can increase drowsiness or fall risk, medication reviews by a neurologist or rehabilitation physician are very important.

---

Dietary Molecular Supplements

Evidence for supplements specifically in Charlevoix-Saguenay spastic ataxia is very limited. Most information comes from general neurology and mitochondrial research. Always discuss any supplement with a doctor or dietitian, especially if you are already taking prescription medicines.

1. Coenzyme Q10 (CoQ10)
CoQ10 is part of the mitochondrial electron transport chain and helps cells make energy (ATP). Some neurodegenerative and mitochondrial disorders use CoQ10 to support energy production and reduce oxidative stress. Typical doses range from 100–300 mg per day in divided doses with food. It may help fatigue and exercise tolerance, although strong evidence in ARSACS is lacking. Side effects are usually mild, such as stomach upset.

2. Omega-3 fatty acids (EPA/DHA)
Omega-3s from fish oil or algae have anti-inflammatory and neuroprotective effects by changing cell membrane composition and reducing inflammatory mediators. Usual doses are 1000–2000 mg combined EPA/DHA daily, taken with meals. In neurological disease they may support cardiovascular health, mood, and brain function. They can slightly increase bleeding risk, especially with anticoagulant drugs.

3. Vitamin B-complex (B1, B6, B12, folate)
B-vitamins are essential for nerve function and energy metabolism. In neuropathies, correcting B12 or folate deficiency can improve symptoms or prevent worsening. Typical supplements provide daily values of each B vitamin; high-dose B6 should be avoided long term because it can itself cause neuropathy. In ARSACS, B-complex helps ensure that no additional vitamin deficiency worsens nerve damage.

4. Vitamin E
Vitamin E is a fat-soluble antioxidant that protects cell membranes from oxidative damage. Some hereditary ataxias due to vitamin E deficiency improve with replacement. In ARSACS there is no evidence that high-dose vitamin E changes the disease, but maintaining normal levels may support overall nerve health. Doses above 400 IU per day should be used cautiously because of possible bleeding risks.

5. L-carnitine
L-carnitine transports long-chain fatty acids into mitochondria to be used for energy. It is sometimes used in mitochondrial disorders and fatigue syndromes. Doses around 500–2000 mg per day in divided doses are common in studies. By supporting mitochondrial function, it may help reduce fatigue and improve exercise tolerance, although data in Charlevoix-Saguenay spastic ataxia are lacking.

6. Alpha-lipoic acid
Alpha-lipoic acid is another antioxidant involved in mitochondrial energy reactions. It has been studied in diabetic neuropathy, where it can reduce pain and improve nerve function in some cases. Typical doses are 300–600 mg daily. Its antioxidant action may theoretically benefit neuropathic components of ARSACS, but strong evidence is not yet available.

7. Magnesium
Magnesium is involved in muscle relaxation, nerve conduction, and energy production. Low magnesium can cause cramps and tremors. Supplemental magnesium (often 200–400 mg daily, adjusted for kidney function) may reduce cramps and improve sleep in some people. Diarrhoea is the main side effect. It should be used with caution in kidney disease.

8. Curcumin (turmeric extract)
Curcumin has anti-inflammatory and antioxidant properties and may modulate various cell signalling pathways. In laboratory models it can reduce oxidative stress and inflammation in brain tissue, but clinical evidence in ataxias is limited. Doses in studies often range from 500–1000 mg/day of standardized extract with piperine to improve absorption. It should be used carefully in people on blood thinners.

9. Probiotics
Probiotics support gut microbiota, which can influence immune function and inflammation. While not specific to ARSACS, a healthy gut may help tolerate multiple medications, reduce constipation from limited mobility, and support general health. Products differ widely; dosing usually follows manufacturer guidance. Side effects are usually mild gas or bloating.

10. Multivitamin with minerals
A balanced multivitamin ensures adequate intake of trace elements such as zinc and selenium, which support immunity and antioxidant enzyme systems. In people with reduced appetite, trouble cooking, or swallowing difficulty, a multivitamin can prevent hidden deficiencies that might worsen fatigue or infections. Dose is usually one tablet daily with food, within recommended daily allowances.

---

Immunity-Booster, Regenerative and Stem-Cell-Related Drugs

At present, there are no FDA-approved regenerative or stem-cell drugs specifically for Charlevoix-Saguenay spastic ataxia. Research is exploring gene therapy approaches that aim to deliver a healthy SACS gene to affected brain cells, but these are still in laboratory or early development stages.McGill University+1 The following points explain general concepts rather than standard treatments:

1. Vaccinations (e.g., influenza, pneumococcal) – Although not “immunity boosters” in the popular sense, routine vaccines are one of the most effective ways to protect people with chronic neurological disease from serious infections. Preventing pneumonia or flu helps maintain strength and avoids hospital stays that can accelerate disability.

2. Vitamin D and zinc (as immune-supportive agents) – Adequate vitamin D and zinc are important for normal immune cell function. Correcting deficiency may reduce infection risk, but mega-doses are not proven to help ARSACS and can be harmful. Doses should follow blood tests and medical advice.

3. Experimental gene therapy – Research groups, including teams partnered with the Ataxia Charlevoix-Saguenay Foundation, are exploring gene therapy that delivers the sacsin gene using viral vectors (for example, AAV).McGill University+1 The idea is to restore sacsin function in Purkinje cells and slow neurodegeneration. At this time there is no approved product, no standard dose, and use is limited to clinical trials.

4. Experimental neuroprotective drugs – Various compounds that reduce oxidative stress, stabilize mitochondria, or improve protein quality control are being studied in models of ARSACS.ScienceDirect+1 They aim to protect neurons rather than replace them. For now, these agents are not available in routine clinical care.

5. Experimental stem cell therapy – Stem cell transplantation has been considered for many neurodegenerative diseases, but there is no strong evidence or approved stem-cell product for ARSACS. Theoretical mechanisms include replacing lost neurons or providing supportive growth factors. Such treatments should only be considered within ethically approved clinical trials, not in unregulated clinics.

6. General infection control and nutrition – Good hand hygiene, oral care, timely treatment of urinary infections, and adequate nutrition act together as a natural “immune support package.” These measures help maintain resilience even though they are not “drugs” in the narrow sense.

---

Surgical and Procedural Management Options

1. Orthopaedic tendon lengthening for contractures
Long-standing spasticity in ARSACS can cause muscles to shorten and joints to become stuck in flexed or twisted positions, especially at the ankles, knees, and hips. Orthopaedic surgeons may perform tendon lengthening or release procedures to improve joint range of motion and foot position.ResearchGate+1 The purpose is to allow better standing and sitting, improve comfort in braces, and make personal care easier.

2. Foot deformity correction surgery
Cavus foot (high arch) and clawed toes are common in hereditary ataxias. Surgery can include osteotomy (cutting and repositioning bones) and tendon transfers to place muscles in better positions. This can improve shoe fitting, reduce pain, and sometimes improve stability during transfers or short-distance walking.

3. Intrathecal baclofen pump implantation
Implantation of an intrathecal baclofen pump is a neurosurgical procedure in which a small device is placed under the skin of the abdomen and connected to a catheter around the spinal cord.FDA Access Data+1 The pump delivers continuous low doses of baclofen to control severe spasticity. It is considered when oral drugs fail or cause too many side effects. It requires regular refills and monitoring.

4. Spinal surgery for scoliosis
Some people with long-standing neuromuscular conditions develop scoliosis (curved spine) that can cause pain, sitting imbalance, and reduced lung capacity. In selected cases, spinal fusion surgery can straighten and stabilize the backbone. This is a major operation and is usually reserved for severe curves after detailed risk–benefit discussion.

5. Gastrostomy tube placement
If swallowing becomes very unsafe and leads to repeated aspiration or weight loss, doctors may recommend placing a feeding tube directly into the stomach (percutaneous endoscopic gastrostomy, PEG). This procedure allows safe delivery of nutrition, fluids, and medications while still permitting oral tasting for pleasure in some cases. The goal is to prevent malnutrition and aspiration pneumonia.

---

Prevention and Lifestyle Measures

1. Early and regular physiotherapy to maintain flexibility, strength, and balance, which can delay contractures and reduce falls.PMC+1

2. Home safety measures such as non-slip flooring, grab bars, and good lighting to prevent falls and fractures.

3. Use of appropriate orthoses and mobility aids before severe problems appear, not only after major falls.NCBI+1

4. Vaccinations and prompt infection treatment to avoid severe respiratory or urinary infections that can lead to hospitalization.

5. Healthy body weight, avoiding both severe weight loss (which weakens muscles) and obesity (which makes transfers and walking harder).

6. Regular monitoring of vision, hearing, and dental health, because small sensory problems can greatly increase disability in a person with ataxia.NCBI+1

7. Safe swallowing strategies and early speech-language assessment to prevent aspiration and weight loss.ataxia.org.uk+1

8. Mental health support, including counselling and, when needed, medication, to maintain motivation and participation in therapy.PMC+1

9. Genetic counselling for family planning, which can prevent unexpected recurrence of ARSACS in future children.MedlinePlus+1

10. Regular follow-up in a neurology or ataxia clinic, so new problems are found and treated early instead of waiting until they cause major disability.National Ataxia Foundation+1

---

When to See Doctors

A person with Charlevoix-Saguenay spastic ataxia, or a parent or caregiver, should contact a doctor or specialist if:

• Balance or walking suddenly becomes worse, especially after an infection or medication change.

• Painful muscle spasms, cramps, or stiffness increase and disturb sleep or daily care.

• New problems with swallowing, choking, or recurrent chest infections appear.

• There are signs of depression or anxiety, such as persistent sadness, loss of interest, or thoughts of hopelessness.

• There are bladder or bowel changes, such as new incontinence, urinary retention, or repeated urinary infections.NCBI+1

• Unexplained weight loss, poor appetite, or difficulty preparing food develops.

• Skin problems such as pressure sores appear, especially in wheelchair users.

• Vision changes, severe headaches, or new neurologic symptoms occur.

• A new medicine seems to cause strong drowsiness, confusion, severe weakness, or allergic reactions.

• Families are planning a pregnancy and want to understand genetic risks and tests.

Regular planned visits (for example every 6–12 months) with a neurologist and rehabilitation team are recommended even when nothing dramatic has changed.NCBI+1

---

What to Eat and What to Avoid

Helpful foods (what to eat)

1. Balanced meals with complex carbohydrates (whole grains, brown rice, oats) to give steady energy for therapy and daily activities.

2. Lean proteins (fish, eggs, pulses, lean meat, tofu) to support muscle repair and immune function.

3. Plenty of fruits and vegetables, which provide vitamins, minerals, and antioxidants that support general brain and nerve health.

4. Healthy fats (olive oil, nuts, seeds, avocado, oily fish) that supply omega-3 fatty acids and help with absorption of fat-soluble vitamins.

5. Adequate fluids, mainly water, to prevent constipation and urinary infections, which are common in people with limited mobility.ataxia.org.uk+1

Foods and habits to limit or avoid

1. Excessive sugary drinks and sweets, which can cause weight gain and energy crashes.
2. Very salty processed foods, which may worsen blood pressure and heart strain in less active people.
3. Heavy alcohol use, which can damage nerves and coordination even more and increase fall risk.
4. Large, rushed meals if swallowing is difficult; instead, smaller, slower meals with recommended textures from a speech therapist are safer.ataxia.org.uk+1
5. Extreme fad diets or high-dose supplements without medical advice, because they may interact with medications or lead to deficiencies.

A dietitian familiar with neurological conditions can adjust food textures, calorie levels, and supplements to match each person’s needs.

---

Frequently Asked Questions

1. Is Charlevoix-Saguenay spastic ataxia curable?
No. At present there is no cure and no disease-specific drug approved for ARSACS. Treatment is focused on symptoms, maintaining function, and preventing complications.CheckRare+1 Research in gene therapy and other approaches is active and gives hope for the future, but these are not yet standard treatments.McGill University+1

2. How is ARSACS inherited?
ARSACS is inherited in an autosomal recessive pattern. This means a person must receive two non-working copies of the SACS gene, one from each parent, to develop the disease. Parents are usually healthy carriers. Each pregnancy has a 25% chance of an affected child, 50% chance of a carrier child, and 25% chance of a child with two working copies.MedlinePlus+1

3. When do symptoms usually start?
Most children with Charlevoix-Saguenay spastic ataxia begin to show symptoms when they first learn to walk, often around 12–24 months. They may be unsteady and fall often. In some families symptoms can start later, in adolescence or early adulthood, but this is less common.Wikipedia+1

4. Will everyone with ARSACS need a wheelchair?
Many, but not all, people with ARSACS eventually use a wheelchair, especially for longer distances. Studies and patient resources suggest that many people need a wheelchair by age 30–40, but progression is variable.National Ataxia Foundation+1 Early therapies, orthoses, and exercise can delay disability but cannot completely stop progression.

5. What is the life expectancy?
Life expectancy in ARSACS can be near normal, although mobility and independence usually decline over time.Wikipedia+1 Good preventive care, vaccinations, safe swallowing strategies, and treatment of infections can help people live longer and healthier lives.

6. Which therapy is most important?
There is no single “best” therapy, but many experts emphasize physiotherapy, occupational therapy, and speech-language therapy as the core of management for Charlevoix-Saguenay spastic ataxia.ataxia.org.uk+1 Medicines such as baclofen or tizanidine are often added to support these therapies.

7. Are baclofen and tizanidine safe for long-term use?
Both drugs are widely used for chronic spasticity and are approved by the FDA for this purpose, but they have side effects. Baclofen can cause drowsiness and weakness and must not be stopped suddenly.FDA Access Data+2FDA Access Data+2 Tizanidine can cause low blood pressure and liver enzyme elevation, so doctors monitor blood tests and adjust the dose carefully.FDA Access Data+1

8. Can exercise make the disease worse?
Appropriate, supervised exercise does not make ARSACS worse and is generally helpful. Studies of rehabilitation programs in ARSACS show improved balance and participation without harm.PMC+1 Over-exertion that causes extreme fatigue or injury should be avoided, so programs should be designed by a physiotherapist familiar with ataxia.

9. Is there any role for stem cell treatment right now?
At this time there is no approved stem cell therapy for Charlevoix-Saguenay spastic ataxia, and evidence is limited to experimental work.unisr.it+1 Offers from unregulated clinics should be viewed with caution. Participation in properly designed clinical trials is the safest way to access experimental treatments.

10. Can diet alone control the disease?
No diet can cure or stop ARSACS, but good nutrition supports muscle, bone, and immune health. A balanced diet with enough calories, protein, vitamins, and fluids helps the body cope with disability and maintain strength. Diet can also reduce constipation and help manage weight, which affects mobility.

11. Should all family members be tested?
Genetic counselling is recommended before testing. Siblings of an affected person may choose testing to know their carrier or disease status, especially when planning a family.MedlinePlus+1 Extended family testing depends on family structure, local laws, and personal preferences.

12. What is the role of clinical trials?
Clinical trials test new treatments such as gene therapies or repurposed drugs. For a rare disease like ARSACS, trials are crucial to discover effective therapies. Patient organizations and specialist centres often keep lists of current studies.ARSACS+1

13. Can ARSACS affect thinking or learning?
Most people with ARSACS have normal intelligence, although mild learning difficulties have been reported in some cases.NxGen MDx+1 Supportive school services and neuropsychological assessments can help if there are concerns.

14. Is pregnancy possible for someone with ARSACS?
Many women with ataxia can have successful pregnancies, but they may need extra support for mobility, transfers, and delivery planning. Spasticity medicines may need adjustment because some drugs (including baclofen and tizanidine) have limited safety data in pregnancy.FDA Access Data+1 Pre-pregnancy counselling with a neurologist and obstetrician is important.

15. What is the best way for families to get reliable information?
Reliable sources include GeneReviews, MedlinePlus Genetics, national ataxia organizations, and disease-specific foundations such as the Ataxia Charlevoix-Saguenay Foundation.ARSACS+3NCBI+3MedlinePlus+3 These groups provide updated information, links to specialists and clinics, and guidance on current research and clinical trials.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: December 31, 2025.